WebThe Treatment-Resistant Hypertension Management market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2024 to 2029. This report segments the global Treatment-Resistant Hypertension Management market comprehensively. Web10 apr. 2024 · Ionis Pharmaceuticals, Inc. has a 12 month low of $31.46 and a 12 month high of $48.82. The stock has a market cap of $5.33 billion, a price-to-earnings ratio of -19.62 and a beta of 0.54. The company has a current ratio of 7.07, a quick ratio of 7.00 and a debt-to-equity ratio of 2.06. Ionis Pharmaceuticals ( NASDAQ:IONS - Get Rating) last ...
Morgan Stanley Maintains Ionis Pharmaceuticals (IONS) Equal …
WebIonis Pharmaceuticals, Inc. Financials IONS US4622221004 IONIS PHARMACEUTICALS, INC. (IONS) Add to my list Report Summary Quotes News Ratings Calendar Company Financials Consensus Revisions Funds Valuation Income Statement Evolution (Annual data) Income Statement Evolution (Quarterly data) Balance Sheet … Web24 feb. 2024 · Ionis Pharmaceuticals, Inc. ... For the R&D revenue of 2024, are you guys not including any revenues from potential new partners or just -- and that's what the current estimate is to be? simpsonville city hall
Ionis reports third quarter financial results Ionis Pharmaceuticals, …
Web22 feb. 2024 · As of December 31, 2024, Ionis had cash, cash equivalents and short-term investments of $2.0 billion compared to $2.1 billion at December 31, 2024. Ionis' year-end cash balance does not include... Web9 aug. 2024 · On track to achieve 2024 financial guidance, based on the following second quarter results: $195 million of operating expenses on a non-GAAP basis (1) and … Web22 feb. 2024 · R&D revenue for 2024 included $112 million from Biogen for advancing several neurology disease programs, $77 million from AstraZeneca for its share of the … razor seat size chart